Industry
Almac
Total Trials
4
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
Failure Rate
0.0%
0 terminated/withdrawn out of 4 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed trials have results
Key Signals
1 recruiting2 with results
Enrollment Performance
Analytics
Phase 2
2(50.0%)
Phase 4
2(50.0%)
4Total
Phase 2(2)
Phase 4(2)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (4)
Showing 4 of 4 trials
NCT05077709Phase 2Completed
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
Role: collaborator
NCT05721235Phase 4Completed
A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD
Role: collaborator
NCT05685732Phase 4Completed
An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD
Role: collaborator
NCT05280314Phase 2Recruiting
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Role: collaborator
All 4 trials loaded